ZOLL Medical Corporation, a manufacturer of resuscitation devices and related software solutions, announced today that Fortune magazine has ranked ZOLL #85 on its list of the 100 fastest growing companies.
In an article entitled “Defying the Downturn” in the August 31 issue, Fortune calls these companies “the world’s supercharged performers.” Even amid the worst economic slump since the Great Depression, some companies just keep growing, the article states. ZOLL is one of only 15 companies in the healthcare industry to make the list.
“While some of our business has softened with the economy since this data was collected, we are well-positioned for continued growth with the strength of our data management business and sales of the LifeVest® Wearable Defibrillator on track to increase 70 percent this fiscal year,” said Richard A. Packer, Chairman and Chief Executive Officer of ZOLL. “We are honored to receive this designation from Fortune and hope to be included in the coming years.”
Earlier this year, ZOLL received special recognition from Forbes.com as one of only 10 companies named to its list of America’s Most Trustworthy Companies for the three consecutive years it has published the list.
To compile the list for Fortune, three years of revenue, profit growth, and total revenue were tallied by Zacks Investment Research. For the first time, the list was opened to businesses around the world that trade on a U.S. exchange.
To qualify, a company—domestic or foreign—must be trading on a major U.S. stock exchange; file quarterly reports to the SEC; have a minimum market capitalization of $250 million on June 30, 2009; have a stock price of at least $5 on June 30, 2009; have been trading continuously since June 30, 2006; have revenue and net income for the four quarters ended on or before April 30, 2009 of at least $50 million and $10 million, respectively; and have posted a compound annual growth in revenue and earnings per share of at least 20% annually over the three years ended April 30, 2009.
The data from Zacks Investment Research was verified by Fortune using data provided by SunGard Fame, Standard & Poor’s Compustat, Hoover’s, Thomson Financial, and 10K Wizard. The full list can be viewed at http://money.cnn.com/magazines/fortune/fortunefastestgrowing/2009/full_list/.
ZOLL’s innovative resuscitation, therapeutic temperature management, and data management products have been instrumental in improving the quality of critical care and increasing patient survival rates. Examples include:
- AutoPulse®, a revolutionary non-invasive cardiac support pump that automates chest compressions;
- LifeVest®, the world’s first and only wearable defibrillator;
- RescueNet® and CodeNet® data management products for EMS, fire and hospitals;
- Defibrillators featuring Real CPR Help®, auditory and visual real-time feedback on the rate and depth of chest compressions to encourage high-quality CPR to maximize blood flow;
- See-Thru CPR®, a unique technology that helps to minimize interruptions during CPR—one of the key recommendations of the American Heart Association’s Guidelines for Advanced Life Support;
About ZOLL Medical Corporation
ZOLL Medical Corporation is committed to developing technologies that help advance the practice of resuscitation and temperature control therapies for the treatment of critical care patients. With products for pacing, defibrillation, circulation, temperature management, and fluid resuscitation, ZOLL provides a comprehensive set of technologies, including Real CPR Help® and See-Thru CPR®, which help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical information.
ZOLL markets and sells its products in more than 140 countries. The Company has direct operations, distributor networks, and business partners throughout the U.S., Canada, Latin America, Europe, the Middle East and Africa, Asia, and Australia. During 2008 ZOLL marked the 25th anniversary of the Company’s resuscitation product development. For more information, visit www.zoll.com .